Finance

Lists
Q2 2027 earnings • in 1 day
See details
4507:TYO
Shionogi & Co Ltd
¥2,975.00
-0.53%
(-16.00) 1D
Oct 29, 9:18:34 AM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4507...
Open
¥2,985
High
¥3,013
Low
¥2,980
Mkt. cap
2.65T
Avg. vol.
3.06M
Volume
363.00K
Dividend
2.38%
Quarterly dividend
¥18
Ex-dividend date
Sep 29, 2026
P/E ratio
9.63
52-wk high
¥3,758
52-wk low
¥2,453
EPS
¥310
Shares outstanding
314.50M
No. of employees
6K
Open
¥2,985
High
¥3,013
Low
¥2,980
Mkt. cap
2.65T
Avg. vol.
3.06M
Volume
363.00K
Dividend
2.38%
Quarterly dividend
¥18
Ex-dividend date
Sep 29, 2026
P/E ratio
9.63
52-wk high
¥3,758
52-wk low
¥2,453
EPS
¥310
Shares outstanding
314.50M
No. of employees
6K
News stories
From web sources and news partners
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6.22K
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com
Next call in 24:22:09
Thu, Oct 29, 9:00 PM
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
- / 175.72B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
113.18B
147.72B
138.99B
163.31B
Cost of goods sold
16.94B
25.09B
28.10B
30.80B
Cost of revenue
16.94B
25.09B
28.10B
30.80B
Research and development expenses
27.55B
29.87B
40.54B
31.79B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.56B
35.27B
32.92B
44.36B
Operating expense
56.57B
48.45B
100.06B
113.87B
Total operating expenses
73.51B
73.54B
128.17B
144.66B
Operating income
39.67B
74.18B
10.83B
18.64B
Other non operating income
-
-1.00M
7.31B
-2.00M
EBT including unusual items
52.06B
92.89B
47.64B
73.74B
EBT excluding unusual items
52.06B
93.10B
47.80B
25.47B
Income tax expense
7.87B
18.21B
-56.00M
-23.98B
Effective tax rate
15.12%
19.60%
-0.12%
-32.52%
Other operating expenses
979.00M
-17.25B
15.44B
21.90B
Net income
44.19B
74.68B
46.93B
97.70B
Net profit margin
39.04%
50.56%
33.77%
59.82%
Earnings per share
-
-
-
-
Interest and investment income
14.21B
20.53B
23.73B
12.15B
Interest expense
-1.82B
-1.61B
-
-5.32B
Net interest expenses
12.38B
18.92B
23.73B
6.82B
Depreciation and amortization charges
-485.00M
-
-1.53B
-
EBITDA
44.83B
80.21B
21.59B
39.52B
Gain or loss from assets sale
-
-
35.04B
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps